Maraviroc for Stroke Recovery (MASTER): A Phase 2 Double-Blind Placebo-Controlled Randomized Clinical Trial

What this Trial Is About

Researchers are evaluating the use of Maraviroc, a drug that blocks the CCR5 receptor, to see if it can improve motor function and learning skills in patients during the first three months after an ischemic stroke. This phase II randomized controlled trial compares Maraviroc to a placebo in patients who have recently experienced a stroke, aiming to enhance recovery where current stroke treatments still leave many with lasting disabilities. Participants will be randomly assigned to receive either Maraviroc at a dose of 300 mg twice daily or a placebo (Mannitol) for 90 days. The study is double-blinded, meaning neither the patients nor the researchers know who is receiving the active drug or placebo. Brain images and motor learning tasks will be conducted at the start and end of the treatment period to assess changes. Throughout the 90-day treatment, patients will undergo clinical evaluations, motor tests, and biometric assessments. Follow-up continues at six months after stroke onset to monitor progress. The primary outcome measured is the Upper Extremity Fugl-Meyer Assessment score on day 90, which evaluates motor function recovery. Safety will be monitored by recording adverse events during and after treatment.

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke